SCHEMBL26965656

SCHEMBL26965656

COOc1cccc2[nH]ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 4/20 0.51
HTR1B P28222 2/20 0.49
TRPA1 O75762 1/20 0.49
AHR P35869 1/20 0.47
HTR1A P08908 8/20 0.47
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
LMNA P02545 2/20 0.44
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
ADRB3 P13945 2/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
DRD4 P21917 2/20 0.44
DRD3 P35462 2/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
CYP2D6 P10635 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321761 0.84 RHEB (0.54) RHEBHTR1BTRPA1AHRHTR1A
SCHEMBL29992707 0.84 RHEB (0.54) RHEBHTR1BTRPA1AHRHTR1A
SCHEMBL29445066 0.84 RHEB (0.54) RHEBHTR1BTRPA1AHRHTR1A
Ethane SCHEMBL7616752 0.82 RHEB (0.53) RHEBHTR1BTRPA1AHRHTR1A
Ethyne SCHEMBL28266951 0.81 RHEB (0.51) RHEBHTR1BTRPA1AHRHTR1A
SCHEMBL1499400 0.79 RHEB (0.73) RHEBHTR1BTRPA1AHRHTR1A
SCHEMBL30681623 0.78 AHR (0.57) RHEBHTR1BTRPA1AHRHTR1A
SCHEMBL4564268 0.78 SLC22A6 (0.47) RHEBHTR1BTRPA1AHRHTR1A
SCHEMBL4206976 0.77 RHEB (0.48) RHEBHTR1BTRPA1AHRHTR1A
Acetonitrile SCHEMBL28669017 0.77 RHEB (0.47) RHEBHTR1BTRPA1AHRHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-20240366638-A1 PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS SYNAPTIVE THERAPEUTICS, LLC 2024-11-07 US disclosed
US-20230405026-A1 A Method of Treating Depression by Immune Modulation MYND LIFE SCIENCES INC (CA) 2023-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366638-A1 PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS HTR1B, HTR2B, PNMT RHEB 596/4885HTR1B 1/4885TRPA1 3408/4885
US-20230405026-A1 A Method of Treating Depression by Immune Modulation ABCF1, ABCF2, ABCB4 RHEB 1320/4885HTR1B 1246/4885TRPA1 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.